Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2014 from OUS - Section for Experimental Cancer Treatment

16 publications found

Aschim EL, Oldenburg J, Kristiansen W, Giwercman A, Witczak O, Fosså SD, Haugen TB (2014)
Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones
Hum Reprod, 29 (12), 2844-51
DOI 10.1093/humrep/deu274, PubMed 25336703

Børøsund E, Cvancarova M, Moore SM, Ekstedt M, Ruland CM (2014)
Comparing effects in regular practice of e-communication and Web-based self-management support among breast cancer patients: preliminary results from a randomized controlled trial
J Med Internet Res, 16 (12), e295
DOI 10.2196/jmir.3348, PubMed 25525672

Dahl S, Loge JH, Berge V, Dahl AA, Cvancarova M, Fosså SD (2014)
Influence of radical prostatectomy for prostate cancer on work status and working life 3 years after surgery
J Cancer Surviv, 9 (2), 172-9
DOI 10.1007/s11764-014-0399-6, PubMed 25216609

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A (2014)
Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
Ann Surg Oncol, 22 (7), 2195-200
DOI 10.1245/s10434-014-4137-0, PubMed 25297902

Edlinger M, Ulmer H, Cvancarova M, Oberaigner W (2014)
Site-specific proportion cured models applied to cancer registry data
Cancer Causes Control, 25 (3), 365-73
DOI 10.1007/s10552-014-0337-y, PubMed 24442714

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Lilleby W, Stensvold A, Dahl AA (2014)
Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up
Acta Oncol, 53 (10), 1380-9
DOI 10.3109/0284186X.2014.916042, PubMed 24844918

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
DOI 10.3390/ijms151222835, PubMed 25501337

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
PLoS One, 9 (2), e89750
DOI 10.1371/journal.pone.0089750, PubMed 24587009

Solberg IC, Cvancarova M, Vatn MH, Moum B, IBSEN Study Group (2014)
Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study)
Inflamm Bowel Dis, 20 (1), 60-8
DOI 10.1097/01.MIB.0000436956.78220.67, PubMed 24280875

Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, Fosså SD, Oldenburg J (2014)
Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors
J Clin Oncol, 32 (6), 571-8
DOI 10.1200/JCO.2013.51.2715, PubMed 24419125

Stenberg U, Cvancarova M, Ekstedt M, Olsson M, Ruland C (2014)
Family caregivers of cancer patients: perceived burden and symptoms during the early phases of cancer treatment
Soc Work Health Care, 53 (3), 289-309
DOI 10.1080/00981389.2013.873518, PubMed 24628120

Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD (2014)
Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment
Clin Genitourin Cancer, 12 (4), e117-25
DOI 10.1016/j.clgc.2013.12.007, PubMed 24524968

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
PLoS One, 9 (2), e87746
DOI 10.1371/journal.pone.0087746, PubMed 24498368

van Leeuwen M, Efficace F, Fosså SD, Bolla M, De Giorgi U, de Wit R, Holzner B, van de Poll-Franse LV, van Poppel H, White J, Collette L, Osanto S, Aaronson NK, European Organisation for Research and Treatment of Cancer Quality of Life Group, Genito-Urinary Cancers Group, Radiation Oncology Group (2014)
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities
Eur J Cancer, 50 (11), 1957-63
DOI 10.1016/j.ejca.2014.04.018, PubMed 24820932

Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J, Hernberg M (2014)
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
Cancer Immunol Immunother, 64 (2), 173-80
DOI 10.1007/s00262-014-1620-1, PubMed 25319807

 
Page visits: 94634